Christopher Wright Sells Shares of Alkermes plc $ALKS
Key Points
- Christopher Wright sold 2,000 shares of Alkermes plc ($ALKS) worth $90,200.
- $ALKS last traded around $44.28.
Christopher Wright, insider at Alkermes plc ($ALKS), sold 2,000 shares at an average price of $45.10, for a total transaction of $90,200. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alkermes plc ($ALKS) Stock
Alkermes plc Earnings
Analysts Set New Price Targets
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.